Stringent Regulations for Manufacturing CAR T-Cells Ensure Patient Safety The CAR T-cell therapy market is projected to mature from a revenue of US$1.1Bn in2020and reach US$21.8Bn by2031. From regulatory point of view, CAR T-cells are an advanced therapy medicinal product (ATMP) in the Eur...
Pluri Unveils Global Cell Therapy Contract Development and Manufacturing Organization: Introducing PluriCDMO™
What is CAR-T Therapy? Autologous chimeric antigen receptor (CAR) T cell therapy is breakthrough treatment for certain types of blood cancers. The treatment involves isolating a person’s own immune cells and manufacturing them to recognize and kill target antigens on the cancer cells of ...
Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S. Novo Holdings Completes Acquisition of Catalent Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction ...
PersonGen is a global key player of CAR-T therapy for T cell malignancies, and is committed to becoming an international leading company of UCAR-T and iPSC derived cellular therapeutics.
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19...
Seoul National University Hospital is the first hospital in South Korea to have successfully produced CAR-T cell therapy.Credit: Seoul National University Hospital Patients first SNUH is South Korea’s largest hospital network as well as the country’s oldest hospital and academic institution. True ...
The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Fate Therapeutics is developing iPSC-derived NK and CAR-T cells for cancer and immune disorders. FUJIFILM Cellular Dynamics, Inc. supports iPSC-derived cell therapy development through its production facility. GC Therapeutics (GCTx) uses its TFome platform to develop iPSC-based therapies for neurolog...
WORLD CELL THERAPY 2025 welcomes you to the International Conference in Paris on March 17-18, 2025, featuring Molecular Cloning, Bioinformatics, Genetics challenges with global speakers and delegates.